Baillie Gifford & Co’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $122M | Sell |
24,173,815
-219,200
| -0.9% | -$1.11M | 0.09% | 122 |
|
|
2025
Q1 | $129M | Sell |
24,393,015
-471,043
| -2% | -$2.49M | 0.11% | 116 |
|
|
2024
Q4 | $168M | Sell |
24,864,058
-375,812
| -1% | -$2.54M | 0.13% | 110 |
|
|
2024
Q3 | $166M | Sell |
25,239,870
-1,350,066
| -5% | -$8.9M | 0.12% | 106 |
|
|
2024
Q2 | $199M | Buy |
26,589,936
+2,522,132
| +10% | +$18.9M | 0.16% | 95 |
|
|
2024
Q1 | $240M | Sell |
24,067,804
-111,700
| -0.5% | -$1.11M | 0.19% | 93 |
|
|
2023
Q4 | $238M | Sell |
24,179,504
-371,905
| -2% | -$3.67M | 0.19% | 98 |
|
|
2023
Q3 | $188M | Sell |
24,551,409
-546,221
| -2% | -$4.18M | 0.17% | 95 |
|
|
2023
Q2 | $187M | Sell |
25,097,630
-37,900
| -0.2% | -$283K | 0.16% | 101 |
|
|
2023
Q1 | $168M | Buy |
25,135,530
+314,680
| +1% | +$2.1M | 0.15% | 102 |
|
|
2022
Q4 | $191M | Buy |
24,820,850
+3,226,157
| +15% | +$24.9M | 0.2% | 92 |
|
|
2022
Q3 | $230M | Sell |
21,594,693
-10,992
| -0.1% | -$117K | 0.24% | 85 |
|
|
2022
Q2 | $176M | Sell |
21,605,685
-375,919
| -2% | -$3.06M | 0.18% | 94 |
|
|
2022
Q1 | $157M | Sell |
21,981,604
-141,551
| -0.6% | -$1.01M | 0.11% | 112 |
|
|
2021
Q4 | $379M | Buy |
22,123,155
+61,781
| +0.3% | +$1.06M | 0.21% | 88 |
|
|
2021
Q3 | $508M | Buy |
22,061,374
+3,540,374
| +19% | +$81.5M | 0.27% | 83 |
|
|
2021
Q2 | $676M | Buy |
+18,521,000
| New | +$676M | 0.33% | 79 |
|